Electrospun fibers of poly(l-lactic acid) containing lovastatin with potential applications in drug delivery

Lovastatin (Merck's Mevacor) is a statin drug designed to lower cholesterol, and reduce the risk of heart attack and stroke. We use electrospinning to combine the biomedical properties of lovastatin with the advantages of electrospun fibers to prepare a composite biomaterial for lovastatin delivery. Poly(l-lactic acid) (PLLA), a biodegradable and biocompatible polymer, was co-spun with lovastatin. Incorporation of lovastatin at 5 or 10 wt % improved fiber alignment and surface smoothness, and increased fiber diameter. Influence of lovastatin on the phase structure (crystal, mobile amorphous, and rigid amorphous fractions) was investigated using scanning calorimetry and synchrotron X-ray scattering. Addition of lovastatin resulted in increased crystallinity and reduced mobile amorphous fraction. PLLA fibers were characterized in terms of their drug release kinetics in comparison to PLLA film. High drug entrapment efficiency (ranging from 72% to 82%) and appropriate release profiles were achieved. In vitro drug release studies demonstrated that release occurred in two stages: an initial rapid release over the first day and a slower second stage of release which approached a plateau after 7 days. PLLA fibers have a higher release rate than comparable film. Electrospun biomaterial fibers of PLLA provide a promising new release strategy for delivery of lovastatin. © 2017 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2017, 134, 45287. © 2017 Wiley Periodicals, Inc.